Thoracic Cancer最新文献_第10页

Circ-PITX1 promotes non-small-cell lung cancer progression through regulating ETS1 expression via miR-615-5p. Circ-PITX1 通过 miR-615-5p 调控 ETS1 的表达，从而促进非小细胞肺癌的进展。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-09-01 Epub Date: 2024-08-13 DOI: 10.1111/1759-7714.15414

Yang Guo, Jianfang Pan, Xiaofei Gao, Yan Zheng

{"title":"Circ-PITX1 promotes non-small-cell lung cancer progression through regulating ETS1 expression via miR-615-5p.","authors":"Yang Guo, Jianfang Pan, Xiaofei Gao, Yan Zheng","doi":"10.1111/1759-7714.15414","DOIUrl":"10.1111/1759-7714.15414","url":null,"abstract":"Background: Circular RNAs (circRNAs), produced by reverse splicing, act as important players in human cancers. We aimed to assess the biological functions of circRNA pituitary homeobox 1 (circ-PITX1) in non-small-cell lung cancer (NSCLC).Methods: qRT-PCR was employed to determine RNA expression. Biological behaviors of NSCLC cells were assessed by CCK-8, colony formation, EdU assay, flow cytometry, wound healing, and transwell assays. Glutamine catabolism was examined via the measurement of glutamine consumption, α-ketoglutarate levels, as well as ATP levels. Protein levels were detected by western blot assays. Dual-luciferase reporter assay and RNA immunoprecipitation (RIP) assay were performed to reveal the mechanism responsible for circ-PITX1 regulating NSCLC cell malignancy. The murine xenograft model was established to investigate circ-PITX1's effect on tumor formation.Results: Circ-PITX1 was overexpressed in NSCLC tissue samples and cells. Its low expression repressed NSCLC cell proliferation and motility. Moreover, our data revealed its downregulation inhibited glutamine catabolism and tumor formation and promoted cell apoptosis. In addition, circ-PITX1 bound to miR-615-5p, and its inhibitory effect on tumor cellular behaviors could be reversed after decreasing miR-615-5p expression. The miRNA targeted E26 transformation specific-1 (ETS1), whose upregulation abolished miR-615-5p overexpression-induced effects in NSCLC cells. Furthermore, circ-PITX1 positively modulated ETS1 production through interaction with miR-615-5p.Conclusion: Circ-PITX1 facilitated NSCLC progression via modulating miR-615-5p/ETS1 pathway.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":"1946-1957"},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11463087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy. 接受抗癌药物治疗的肺癌患者慢性肺曲霉菌病的临床意义。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-09-01 Epub Date: 2024-08-01 DOI: 10.1111/1759-7714.15416

Kenji Morimoto, Ryosuke Hamashima, Tadaaki Yamada, Toshihide Yokoyama, Takehiko Kobayashi, Kazunari Tsuyuguchi, Takanori Kanematsu, Nobuyo Tamiya, Taisuke Tsuji, Ryota Nakamura, Yuki Katayama, Naoya Nishioka, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama

{"title":"Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy.","authors":"Kenji Morimoto, Ryosuke Hamashima, Tadaaki Yamada, Toshihide Yokoyama, Takehiko Kobayashi, Kazunari Tsuyuguchi, Takanori Kanematsu, Nobuyo Tamiya, Taisuke Tsuji, Ryota Nakamura, Yuki Katayama, Naoya Nishioka, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama","doi":"10.1111/1759-7714.15416","DOIUrl":"10.1111/1759-7714.15416","url":null,"abstract":"Background: Advances in anticancer drugs for lung cancer (LC) have improved the prognosis of LC. Chronic pulmonary aspergillosis (CPA) is a progressive and often exacerbating respiratory disease with a poor prognosis. To date, the prognosis of LC complicated by CPA has not been elucidated. This study investigated the clinical implications of concomitant CPA in patients with LC undergoing anticancer drug treatment.Methods: Between January 2010 and May 2020, we consecutively enrolled patients with LC complicated with CPA at five different institutions in Japan. We analyzed patients with LC complicated by CPA who received anticancer drug treatment.Results: A total of 10 patients with LC complicated by CPA received anticancer drug treatment. The median overall survival (OS) was 14.57 months (95% confidence interval [CI]: 5.37-21.67). The cause of death in all patients was LC. Six of the seven patients with LC did not show worsening pulmonary aspergillosis lesions during the anticancer drug treatment. Although two patients discontinued anticancer drug treatment due to pneumonitis, CPA complications did not interfere with the continuation of anticancer drug treatment. In univariate analyses, squamous histology (p = 0.01) and body mass index (<18.5 kg/m2) (p = 0.0008) were significantly associated with poorer OS.Conclusions: This study demonstrated that the cause of death in LC patients with concomitant CPA who received anticancer drug treatments and effective antifungal treatment was LC progression. Further large-scale studies are needed to identify the effect of CPA in patients with LC.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":"1882-1888"},"PeriodicalIF":2.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The utility of next-generation sequencing in distinguishing between separate primary lung carcinomas and intrapulmonary metastasis: A case report. 下一代测序在区分独立原发性肺癌和肺内转移癌方面的作用：病例报告。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-09-01 Epub Date: 2024-08-13 DOI: 10.1111/1759-7714.15423

Shilpa S Mantri, William D Wallace, Jorge J Nieva

引用次数: 0

Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non-small cell lung cancer harboring BRAF V600E mutation: A case report. BRAF 和 MEK 抑制剂新辅助治疗可使携带 BRAF V600E 突变的 IIIA 期非小细胞肺癌患者获得病理完全应答：病例报告。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-01 Epub Date: 2024-07-17 DOI: 10.1111/1759-7714.15409

Zhicheng Huang, Yadong Wang, Bowen Li, Yuan Xu, Guanghua Huang, Yang Song, Ji Li, Lan Song, Jinhua Wang, Rongxi Wang, Naixin Liang, Shanqing Li

{"title":"Neoadjuvant BRAF and MEK inhibitor therapy elicits pathological complete response in stage IIIA non-small cell lung cancer harboring BRAF V600E mutation: A case report.","authors":"Zhicheng Huang, Yadong Wang, Bowen Li, Yuan Xu, Guanghua Huang, Yang Song, Ji Li, Lan Song, Jinhua Wang, Rongxi Wang, Naixin Liang, Shanqing Li","doi":"10.1111/1759-7714.15409","DOIUrl":"10.1111/1759-7714.15409","url":null,"abstract":"In recent years, significant improvement has been made in the management of non-small cell lung cancer (NSCLC), primarily driven by advances in targeted therapy and immunotherapy. Research on neoadjuvant targeted therapy has also experienced considerable development, primarily directed towards NSCLC harboring epidermal growth factor receptor or anaplastic lymphoma kinase mutations. Nevertheless, there remains a dearth of studies investigating neoadjuvant targeted therapy in the context of BRAF (V-Raf murine sarcoma viral oncogene homolog B) V600E mutant NSCLC. Herein, we describe the clinical trajectory of a stage IIIA NSCLC patient who underwent a two-month course of neoadjuvant targeted therapy comprising BRAF and MEK (mitogen-activated extracellular signal-regulated kinase) inhibitors prior to surgical intervention, and subsequent postoperative evaluation unveiled a pathological complete response. The case reported here indicates the efficacy and safety of combining BRAF and MEK inhibitors as neoadjuvant targeted therapy in BRAF V600E-mutant NSCLC and suggests the potential viability of such a therapeutic modality in improving treatment outcomes in this subset of NSCLC.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":"1825-1828"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11333294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141634586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Changes in the recent three decades and survey on the current status of surgical treatment for esophageal cancer in China. 中国食管癌外科治疗近三十年的变化和现状调查。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-01 Epub Date: 2024-07-19 DOI: 10.1111/1759-7714.15391

Yong Li, Wei-Xin Liu, Ling Qi, Yin Li, Jun-Feng Liu, Jian-Hua Fu, Yong-Tao Han, Wen-Tao Fang, Zhen-Tao Yu, Ke-Neng Chen, You-Sheng Mao

{"title":"Changes in the recent three decades and survey on the current status of surgical treatment for esophageal cancer in China.","authors":"Yong Li, Wei-Xin Liu, Ling Qi, Yin Li, Jun-Feng Liu, Jian-Hua Fu, Yong-Tao Han, Wen-Tao Fang, Zhen-Tao Yu, Ke-Neng Chen, You-Sheng Mao","doi":"10.1111/1759-7714.15391","DOIUrl":"10.1111/1759-7714.15391","url":null,"abstract":"Background: To review the changes and survey on status quo of the surgical treatment for esophageal cancer in China. The differences in diagnosis and treatment for esophageal cancer among hospitals in different regions across China were also investigated.Methods: We sent questionnaires to 46 hospitals across China, investigating the volume of esophageal cancer surgeries, surgical procedures, and perioperative management under the guidance of esophageal surgery chiefs.Results: A total of 46 questionnaires were sent out and collected. The survey results showed that in the past 5 years, the volume of surgeries for esophageal cancer remained stable by 23.9% of those hospitals, increased by 30.4%, and decreased by 45.7%. Of those patients treated by surgery, 19.1% were in the early stages, and 80.9% were in locally advanced stages. In terms of surgical procedures, 73.4% of the patients were treated by minimally invasive surgery and 85.7% of esophageal substitutes were a gastric conduit, 93.1% of the substitutes were pulled to the neck through the esophageal bed. For the lymph node dissection, 78.5% of the patients had a complete two-field lymph node dissection including the para-recurrent laryngeal nerve lymph nodes. Of the patients with neoadjuvant therapy, 53.5% received chemotherapy or chemotherapy plus immunotherapy (47.0%), and 43.5% had chemoradiation.Conclusions: Currently, in China, minimally invasive surgery-oriented multimodality treatment, including complete two-field lymph node dissection, has become the standard approach for esophageal cancer management. Over the past decade, this standardized approach has significantly improved prognosis compared to previous decades.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":"1705-1713"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141731428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenge of concomitant thymoma resection and myocardial revascularization: A Case Report. 同时进行胸腺瘤切除术和心肌血管重建术的挑战：病例报告

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-01 Epub Date: 2024-07-24 DOI: 10.1111/1759-7714.15245

Beatrice Leonardi, Giovanni Natale, Giuseppe Vicario, Mario Grande, Alfonso Fiorelli, Luigi Di Tommaso, Vincenzo Speranza, Daniele Torella, Marisa De Feo, Michele Torella

引用次数: 0

TNNT1 accelerates migration, invasion and EMT progression in lung cancer cells. TNNT1 可加速肺癌细胞的迁移、侵袭和 EMT 进展。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-01 Epub Date: 2024-07-07 DOI: 10.1111/1759-7714.15400

Xiaobin Ge, Guangzhong Du, Qingchen Zhou, Bing Yan, Gonglei Yue

{"title":"TNNT1 accelerates migration, invasion and EMT progression in lung cancer cells.","authors":"Xiaobin Ge, Guangzhong Du, Qingchen Zhou, Bing Yan, Gonglei Yue","doi":"10.1111/1759-7714.15400","DOIUrl":"10.1111/1759-7714.15400","url":null,"abstract":"Background: Clinically, most patients with lung cancer (LC) die from tumor spread and metastasis. Specific metastasis-related molecules can provide reference for clinical prediction of efficacy, evaluation of prognosis, and search for the best treatment plan. Troponin T1 (TNNT1) is highly expressed in various cancer tissues, which affects malignant behavior of tumor cells and is related to patients' survival and prognosis. However, the role and molecular mechanism of TNNT1 in LC invasion and metastasis have not yet been investigated.Methods: Gene expression profiling interactive analysis (GEPIA) online analysis was used to analyze TNNT1 expression in LC tissues. Quantitative real-time-polymerase chain reaction (qRT-PCR) or western blot were performed to measure TNNT1 or epithelial-to-mesenchymal transition (EMT)-related and Wnt/β-catenin pathway-related protein expression in LC cells. After TNNT1 knockdown, cell scratch healing and transwell assays were introduced to assess cell migration and invasion, respectively.Results: TNNT1 expression in LC tissues and cells was increased. TNNT1 knockdown notably impaired LC cell migration, invasion and EMT. TNNT1 knockdown inhibited Wnt/β-catenin pathway of LC cells. Lithium chloride (LiCl) addition partially restored the inhibition of TNNT1 knockdown on migration, invasion, EMT and Wnt/β-catenin of LC cells.Conclusion: TNNT1 knockdown attenuated LC migration, invasion and EMT, possibly through Wnt/β-catenin signaling.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":"1749-1756"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11320084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141555539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lung squamous cell carcinoma responding to nivolumab retreatment six years after initial treatment: A case report. 肺鳞癌在初次治疗六年后对尼伐单抗再治疗产生反应：病例报告。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-01 Epub Date: 2024-07-02 DOI: 10.1111/1759-7714.15267

Kento Kono, Kazuhisa Nakashima, Yukari Tsubata, Yoshihiro Amano, Keita Kawakado, Takashi Yanagawa, Takeshi Isobe

{"title":"Lung squamous cell carcinoma responding to nivolumab retreatment six years after initial treatment: A case report.","authors":"Kento Kono, Kazuhisa Nakashima, Yukari Tsubata, Yoshihiro Amano, Keita Kawakado, Takashi Yanagawa, Takeshi Isobe","doi":"10.1111/1759-7714.15267","DOIUrl":"10.1111/1759-7714.15267","url":null,"abstract":"A 61-year-old man presented to our hospital with a chief complaint of chronic cough. He was diagnosed with lung squamous cell carcinoma at clinical stage cT2aN3M1a. He received chemotherapy up to the fourth line, but both the primary tumor and lymph node metastases increased in size. Nivolumab, administered as the fifth line, resulted in a complete response (CR) that continued for 2 years and 8 months. Treatment was stopped due to the appearance of common terminology criteria for adverse events grade 1 pneumonitis. He was followed up without treatment for 3 years and 8 months, but a left supraclavicular fossa lymph node metastasis appeared. Retreatment with nivolumab was initiated, and the patient achieved CR again. One year and 6 months after retreatment, CR was maintained with nivolumab. This case represents a rare instance in which nivolumab yielded a significant response after a prolonged immune checkpoint inhibitor (ICI)-free interval. Our experience has shown that the long-term response to ICIs may deteriorate in the future. Therefore, retreatment with ICIs may be effective when the initial therapy is successful.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":"1714-1717"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141493623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The association of nutritional and inflammatory biomarkers with overall survival in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. 接受免疫检查点抑制剂治疗的非小细胞肺癌患者的营养和炎症生物标志物与总生存期的关系。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-01 Epub Date: 2024-07-19 DOI: 10.1111/1759-7714.15401

I M Horstman, P C Vinke, E Suazo-Zepeda, T J N Hiltermann, M A Heuvelmans, E Corpeleijn, G H de Bock

{"title":"The association of nutritional and inflammatory biomarkers with overall survival in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.","authors":"I M Horstman, P C Vinke, E Suazo-Zepeda, T J N Hiltermann, M A Heuvelmans, E Corpeleijn, G H de Bock","doi":"10.1111/1759-7714.15401","DOIUrl":"10.1111/1759-7714.15401","url":null,"abstract":"Objectives: Pretreatment biomarkers are needed to identify patients with non-small-cell lung cancer (NSCLC) likely to have worse survival. This ensures that only patients with a real chance of benefit receive immune checkpoint inhibitor (ICI) treatment. In this study, we examined the associations of baseline nutritional and inflammatory biomarkers with overall survival in a real-world cohort of NSCLC patients who received ICIs.Materials and methods: We used prospectively collected data from the OncoLifeS data biobank. The cohort included 500 advanced-stage NSCLC patients treated with ICIs from May 2015 to June 2021. Biomarkers were evaluated within 2 weeks before ICI treatment: neutrophil-to-lymphocyte ratio, C-reactive protein (CRP), Glasgow prognostic score, CRP/albumin ratio (CAR), prognostic nutritional index (PNI), and advanced lung cancer inflammation index. For each biomarker, low- and high-risk groups were defined using literature-based cut-offs. Adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were estimated using adjusted survival analysis.Results: Most patients were male (60.8%), the mean baseline age was 65 ± 9 years, and 88% had stage IV disease. For each biomarker, low-risk patients had better overall survival (all, p < 0.001), with CAR and PNI showing the strongest associations. In multivariable analyses a combined CAR/PNI risk score had a stronger association with overall survival (aHR 3.09, 95% CI 2.36-4.06) than CAR alone (aHR 2.22, 95% CI 1.79-2.76) or PNI alone (aHR 2.09, 95% CI 1.66-2.61).Conclusion: These results highlight the potential value of nutritional and inflammatory biomarkers, in particular CAR and PNI, in identifying NSCLC patients with highest mortality risk before starting ICI treatment.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":"1764-1771"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11320085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141731429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib. ALK阳性肺腺癌患者在使用阿来替尼和布瑞格替尼耐药后成功获得颅内反应：布瑞格替尼中枢神经系统渗透率的影响。

IF 2.3 3区医学

Thoracic Cancer Pub Date : 2024-08-01 Epub Date: 2024-06-24 DOI: 10.1111/1759-7714.15395

Yuki Sato, Yoshiharu Sato, Kei Irie, Shigeki Nanjo, Shigeo Hara, Satoru Fujiwara, Keisuke Tomii

{"title":"Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib.","authors":"Yuki Sato, Yoshiharu Sato, Kei Irie, Shigeki Nanjo, Shigeo Hara, Satoru Fujiwara, Keisuke Tomii","doi":"10.1111/1759-7714.15395","DOIUrl":"10.1111/1759-7714.15395","url":null,"abstract":"We present the case of a 34-year-old Japanese man with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer and brain metastases. After central nervous system (CNS) disease progression with alecintib and brigatinib, treatment with lorlatinib resulted in a good intracranial response. In this case, we investigated brain penetration ratio of brigatinib using cerebrospinal fluid and paired serum samples, and the ratio was 0.012. Further, we investigated resistance mechanisms via next-generation sequencing (NGS) using lung biopsy at lung cancer diagnosis and brain biopsy sample at progressive disease of brigatinib. No apparent resistance mechanism of known ALK resistance, such as ALK mutations, amplifications, epithelial-mesenchymal transition (EMT) and bypass pathway activation were detected. Taken together, we speculate that the low CNS penetration rate of brigatinib confers CNS progression. Further studies are warranted to reveal the resistance mechanism and propose a treatment strategy for CNS progression in ALK-positive patients.","PeriodicalId":23338,"journal":{"name":"Thoracic Cancer","volume":" ","pages":"1772-1775"},"PeriodicalIF":2.3,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11320077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141459519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0